LISSONI ANDREA ALBERTO

Bianchi, T., Grassi, T., De Ponti, E., Jaconi, M., Seca, M., Inzoli, A., et al. (2025). Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort. GYNECOLOGIC ONCOLOGY, 199(August 2025), 10-16 [10.1016/j.ygyno.2025.06.009]. Detail

Post, C., De Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., et al. (2025). Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. OBSTETRICAL & GYNECOLOGICAL SURVEY, 80(12), 757-759 [10.1097/OGX.0000000000001475]. Detail

Post, C., De Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., et al. (2025). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. THE LANCET ONCOLOGY, 26(10), 1370-1381 [10.1016/s1470-2045(25)00379-1]. Detail

Colombo, N., Biagioli, E., Harano, K., Galli, F., Hudson, E., Antill, Y., et al. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. THE LANCET ONCOLOGY, 25(9), 1135-1146 [10.1016/S1470-2045(24)00334-6]. Detail

Marino, G., Grassi, T., De Ponti, E., Negri, S., Testa, F., Giuliani, D., et al. (2024). Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy. FRONTIERS IN ONCOLOGY, 14 [10.3389/fonc.2024.1330481]. Detail